Chinese state media say a COVID-19 vaccine developed by Sinopharm's China National Biotec Group (CNBG) is safe in those aged between three and 17, based on clinical data obtained by the company, as reported in NASDAQ.
CNBG chairman Yang Xiaoming said "it should be noted that for three- to five-year-old children, because their immune system is still developing, they must be carefully and closely monitored during vaccination," although he did not give further details.
The Sinopharma unit has two COVID-19 vaccines in Phase III trials, both of which have been authorised for emergency use and are being given to limited priority groups at high risk of infection.
The vaccine being developed by CNBG's Beijing unit was the first in China to be approved for general public use in late December. It was not clear which CNBG vaccine Yang was referring to in his comments about clinical trials on children and teenagers.
The CNBG vaccine approved for general public use was 79.3% effective in preventing people from contracting the disease, CNBG's Beijing Institute of Biological Products said late last month, but it has not yet released any detailed efficacy data.
To read more NewsPoints articles, click here.